TNFi Cycling Versus Changing Mechanism of Action in TNFi‐Experienced Patients: Result of the Corrona CERTAIN Comparative Effectiveness Study

Comparative effectiveness research can inform treatment decisions regarding the choice of biologics for rheumatoid arthritis (RA). The objective of this study is to compare the efficacy of tumor necrosis factor inhibitors (TNFis) and non‐TNFis (nTNFis) in real‐world patients with RA and past TNFi experience.

[1]  E. Toussirot.  The Interrelations between Biological and Targeted Synthetic Agents Used in Inflammatory Joint Diseases, and Obesity or Body Composition , 2020, Metabolites.

[2]  J. Listing,et al.  Obesity reduces the real-world effectiveness of cytokine-targeted but not cell-targeted disease-modifying agents in rheumatoid arthritis , 2019, Rheumatology.

[3]  M. Suarez‐Almazor,et al.  Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis. , 2017, The Cochrane database of systematic reviews.

[4]  M. Suarez‐Almazor,et al.  Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis. , 2017, The Cochrane database of systematic reviews.

[5]  P. Ravaud,et al.  Non-TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug: A Randomized Clinical Trial. , 2016, JAMA.

[6]  J. Kremer,et al.  Comparative effectiveness and safety of rituximab versus subsequent anti–tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti–tumor necrosis factor therapies in the United States Corrona registry , 2015, Arthritis Research & Therapy.

[7]  Jeffrey R Curtis,et al.  “Design characteristics of the CORRONA CERTAIN study: a comparative effectiveness study of biologic agents for rheumatoid arthritis patients” , 2014, BMC Musculoskeletal Disorders.

[8]  P. Emery,et al.  Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study , 2014, Annals of the rheumatic diseases.

[9]  J. Gómez-Reino,et al.  Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study , 2012, Annals of the rheumatic diseases.

[10]  Douglas H. Fernald,et al.  Intraclass Correlation Coefficients Typical of Cluster-Randomized Studies: Estimates From the Robert Wood Johnson Prescription for Health Projects , 2012, The Annals of Family Medicine.

[11]  P. V. van Riel,et al.  Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries , 2011, Annals of the rheumatic diseases.

[12]  M. Dougados,et al.  B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study. , 2011, Arthritis and rheumatism.

[13]  John B. Carlin,et al.  The Intra‐Cluster Correlation Coefficient in Cluster Randomized Trials: A Review of Definitions , 2009 .

[14]  P. Austin.  Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples , 2009, Statistics in medicine.

[15]  C. Gabay,et al.  B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. , 2007, Arthritis and rheumatism.

[16]  H. Yamanaka,et al.  Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values , 2006, Annals of the rheumatic diseases.

[17]  J. Kremer.  The CORRONA database , 2005, Annals of the rheumatic diseases.

[18]  G. Stucki,et al.  Rheumatoid arthritis measures: Disease activity score (DAS), disease activity score-28 (DAS28), rapid assessment of disease activity in rheumatology (RADAR), and rheumatoid arthritis disease activity index (RADAI) , 2003 .

[19]  M. Suarez‐Almazor,et al.  Biologics for rheumatoid arthritis: an overview of Cochrane reviews , 2009, The Cochrane database of systematic reviews.